Evidence Gaps Analysis
3688 outcomes from 214 review series
#VALUE!
Current Version: CD014546
Current Evidence Gaps 4 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Asymptomatic children or adults presenting for clinical examination (clinical studies); extracted teeth of children or adults (in vitro studies). Clinical or in vitro studies which intentionally included dentine and frank cavitations for assessment were excluded | Visual classification. Results of the index tests were usually recorded on an ordinal scale to indicate severity of disease. For the purposes of this review the positivity threshold was caries in enamel | Estimates were compared across different classification systems. A separate review in this series explores the comparative accuracy of visual classification, fluorescenceâbased, radiograph, and transillumination methods of detection and diagnosis | False negatives (tooth sites or surfaces incorrectly classified as not having early enamel caries) | Low | Not specified |
| Asymptomatic children or adults presenting for clinical examination (clinical studies); extracted teeth of children or adults (in vitro studies). Clinical or in vitro studies which intentionally included dentine and frank cavitations for assessment were excluded | Visual classification. Results of the index tests were usually recorded on an ordinal scale to indicate severity of disease. For the purposes of this review the positivity threshold was caries in enamel | Estimates were compared across different classification systems. A separate review in this series explores the comparative accuracy of visual classification, fluorescenceâbased, radiograph, and transillumination methods of detection and diagnosis | False positives (tooth sites or surfaces incorrectly classified as having early enamel caries) | Low | Not specified |
| Asymptomatic children or adults presenting for clinical examination (clinical studies); extracted teeth of children or adults (in vitro studies). Clinical or in vitro studies which intentionally included dentine and frank cavitations for assessment were excluded | Visual classification. Results of the index tests were usually recorded on an ordinal scale to indicate severity of disease. For the purposes of this review the positivity threshold was caries in enamel | Estimates were compared across different classification systems. A separate review in this series explores the comparative accuracy of visual classification, fluorescenceâbased, radiograph, and transillumination methods of detection and diagnosis | True negatives (tooth sites or surfaces without early enamel caries) | Low | Not specified |
| Asymptomatic children or adults presenting for clinical examination (clinical studies); extracted teeth of children or adults (in vitro studies). Clinical or in vitro studies which intentionally included dentine and frank cavitations for assessment were excluded | Visual classification. Results of the index tests were usually recorded on an ordinal scale to indicate severity of disease. For the purposes of this review the positivity threshold was caries in enamel | Estimates were compared across different classification systems. A separate review in this series explores the comparative accuracy of visual classification, fluorescenceâbased, radiograph, and transillumination methods of detection and diagnosis | True positives (tooth sites or surfaces with early enamel caries) | Low | Not specified |
#VALUE!
Current Version: CD013855
Current Evidence Gaps 4 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children or adults who are presenting asymptomatically or are suspected of having enamel caries (clinical studies); extracted teeth of children or adults (in vitro studies). Studies which intentionally included dentine and frank cavitations were excluded | Transillumination?based devices ? including near?infrared (NIR), optical coherence tomography (OCT), and fibre?optic transillumination (FOTI)/digital fibre?optic transillumination (DIFOTI), suitable for use as an adjunct to a conventional clinical oral examination. The index tests produced an enhanced view of the tooth and were interpreted by a trained examiner | Comparisons were made between transillumination devices. A separate review in this series investigates comparisons between transillumination?based tests and enhanced visual, radiograph, and fluorescence tests | True positives (patients with early enamel caries) | Low | Not specified |
| Children or adults who are presenting asymptomatically or are suspected of having enamel caries (clinical studies); extracted teeth of children or adults (in vitro studies). Studies which intentionally included dentine and frank cavitations were excluded | Transillumination?based devices ? including near?infrared (NIR), optical coherence tomography (OCT), and fibre?optic transillumination (FOTI)/digital fibre?optic transillumination (DIFOTI), suitable for use as an adjunct to a conventional clinical oral examination. The index tests produced an enhanced view of the tooth and were interpreted by a trained examiner | Comparisons were made between transillumination devices. A separate review in this series investigates comparisons between transillumination?based tests and enhanced visual, radiograph, and fluorescence tests | False positives (patients incorrectly classified as having early enamel caries) | Low | Not specified |
| Children or adults who are presenting asymptomatically or are suspected of having enamel caries (clinical studies); extracted teeth of children or adults (in vitro studies). Studies which intentionally included dentine and frank cavitations were excluded | Transillumination?based devices ? including near?infrared (NIR), optical coherence tomography (OCT), and fibre?optic transillumination (FOTI)/digital fibre?optic transillumination (DIFOTI), suitable for use as an adjunct to a conventional clinical oral examination. The index tests produced an enhanced view of the tooth and were interpreted by a trained examiner | Comparisons were made between transillumination devices. A separate review in this series investigates comparisons between transillumination?based tests and enhanced visual, radiograph, and fluorescence tests | True negatives (patients without early enamel caries) | Low | Not specified |
| Children or adults who are presenting asymptomatically or are suspected of having enamel caries (clinical studies); extracted teeth of children or adults (in vitro studies). Studies which intentionally included dentine and frank cavitations were excluded | Transillumination?based devices ? including near?infrared (NIR), optical coherence tomography (OCT), and fibre?optic transillumination (FOTI)/digital fibre?optic transillumination (DIFOTI), suitable for use as an adjunct to a conventional clinical oral examination. The index tests produced an enhanced view of the tooth and were interpreted by a trained examiner | Comparisons were made between transillumination devices. A separate review in this series investigates comparisons between transillumination?based tests and enhanced visual, radiograph, and fluorescence tests | False negatives (patients incorrectly classified as not having early enamel caries) | Low | Not specified |
#VALUE!
Current Version: CD013811
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children or adults who are presenting asymptomatically or who are suspected of having enamel caries (clinical studies); extracted teeth of children or adults (in vitro studies) | Fluorescence-based devices | Comparisons were made between fluorescence devices | Detection of dental caries at the threshold of caries in enamel | Low | Not specified |
#VALUE!
Current Version: CD013806
Current Evidence Gaps 4 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Adults who present asymptomatically or are suspected of having root caries (in vivo studies); extracted teeth of adults (in vitro studies) | Laser fluorescence | nan | Root caries detection | Very Low | Not specified |
| Adults who present asymptomatically or are suspected of having root caries (in vivo studies); extracted teeth of adults (in vitro studies) | Radiograph and visual examination combined | nan | Root caries detection | Very Low | Not specified |
| Adults who present asymptomatically or are suspected of having root caries (in vivo studies); extracted teeth of adults (in vitro studies) | Radiographs | nan | Root caries detection | Very Low | Not specified |
| Adults who present asymptomatically or are suspected of having root caries (in vivo studies); extracted teeth of adults (in vitro studies) | Visual examination | nan | Root caries detection | Very Low | Not specified |
#VALUE!
Current Version: CD012744
Current Evidence Gaps 16 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | Xerostomia (0-4 scale - grade 2 or above) - 12 months postRT | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | vomiting associated with amifostine (Adverse effects) | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | allergic response associated with amifostine(Adverse effects) | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | nausea associated with amifostine(Adverse effects) | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | hypotension associated with amifostine(Adverse effects) | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | palifermin | placebo | Xerostomia (0-4 scale - grade 2 or above) - Up to and including 3 months postRT | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | sweating | Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | palifermin | placebo | Overall survival at 42 to 72 months from baseline | Moderate | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | palifermin | placebo | Adverse effects | No Evidence Yet | N/A |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | adverse events, apart from for sweating | No Evidence Yet | N/A |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | Overall survival at 12 to 24 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | Salivary flow rate (mg/5 min) (unstimulated) - 12 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | amifostine | no treatment/placebo | Quality of life (Patient Benefit Questionnaire) - 12 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | Xerostomia - Up to and including 6 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | Salivary flow rate (unstimulated) - Up to and including 3 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | Quality of life - Up to and including 6 months postRT | Very Low | Not specified |
| patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region | pilocarpine | no treatment/placebo | Overall survival - Up to and including 6 months postRT | Very Low | Not specified |
CD000978
Current Version: CD000978.PUB5
| 4 older versions
Current Evidence Gaps 7 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients with cancer receiving treatment | Chlorhexidine | Placebo/no treatment | Mucositis (any) | Low | Not specified |
| Patients with cancer receiving treatment | Chlorhexidine | Placebo/no treatment | Mucositis (severe) | Low | Not specified |
| Patients with cancer receiving treatment | Cryotherapy | No treatment | Mucositis (any) | Low | Not specified |
| Patients with cancer receiving treatment | Cryotherapy | No treatment | Mucositis (severe) | Low | Not specified |
| Patients with cancer receiving treatment | Keratinocyte GF | Placebo | Mucositis (any) | Low | Not specified |
| Patients with cancer receiving treatment | Keratinocyte GF | Placebo | Mucositis (severe) | Low | Not specified |
| Patients with cancer receiving treatment | Amifostine | Placebo/no treatment | Mucositis (any) | Moderate | Not specified |
| Patients with cancer receiving treatment | Sucralfate | Placebo/usual care | Mucositis (any) | Moderate | Not specified |
| Patients with cancer receiving treatment | Sucralfate | Placebo/usual care | Mucositis (severe) | Moderate | Not specified |
| Patients with cancer receiving treatment | Amifostine | Placebo/no treatment | Mucositis (severe) | Very Low | Not specified |
Previous Versions
CD000978.PUB4
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients | Allopurinol | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Allopurinol | Placebo/no treatment | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Aloe vera | Placebo | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Amifostine | Placebo/no treatment | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Amifostine | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Amifostine | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Chlorhexidine | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Cryotherapy | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Cryotherapy | Placebo/no treatment | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Cryotherapy | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | G-CSF | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Glutamine | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Glutamine | Placebo/no treatment | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Glutamine | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | GM-CSF | Placebo/no treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Honey | No treatment | Any mucositis | No Evidence Yet | - |
| Cancer patients | Keratinocyte GF | Placebo | Moderate plus severe mucositis | No Evidence Yet | - |
| Cancer patients | Keratinocyte GF | Placebo | Any mucositis | No Evidence Yet | - |
| Cancer patients | Keratinocyte GF | Placebo | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Laser | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Sucralfate | Placebo/usual care | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Sucralfate | Placebo/usual care | Any mucositis | No Evidence Yet | - |
| Cancer patients | Sucralfate | Placebo/usual care | Moderate plus severe mucositis | No Evidence Yet | - |
CD000978.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults with head and neck cancer | Hydrolytic enzymes | No treatment | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Adults with head and neck cancer | Hydrolytic enzymes | No treatment | Prevention of severe mucositis | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Prevention of any mucositis | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Prevention of severe mucositis | No Evidence Yet | - |
| Cancer patients | Benzydamine | Placebo | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Calcium phosphate | Placebo | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Calcium phosphate | Placebo | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Calcium phosphate | Placebo | Prevention of severe mucositis | No Evidence Yet | - |
| Cancer patients | Chinese medicine | Control | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Chinese medicine | Control | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Chinese medicine | Control | Prevention of severe mucositis | No Evidence Yet | - |
| Cancer patients | Etoposide bolus | Etoposide continuous infusion | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Etoposide bolus | Etoposide continuous infusion | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Etoposide bolus | Etoposide continuous infusion | Prevention of severe mucositis | No Evidence Yet | - |
| Cancer patients | Iseganan | Placebo | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Oral care | No treatment | Prevention of any mucositis | No Evidence Yet | - |
| Cancer patients | Zinc sulphate | Placebo | Prevention of severe mucositis | No Evidence Yet | - |
| Cancer patients | Zinc sulphate | Placebo | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients receiving 5-FU | Folinic acid | No treatment | Mucositis incidence | No Evidence Yet | - |
| Cancer patients receiving 5-FU | Folinic acid | No treatment | Moderate/severe mucositis | No Evidence Yet | - |
| Patients receiving 5-FU chemotherapy | Ice chips | No treatment | Prevention of severe mucositis | No Evidence Yet | - |
| Patients receiving 5-FU chemotherapy | Ice chips | No treatment | Prevention of moderate/severe mucositis | No Evidence Yet | - |
| Patients receiving 5-FU chemotherapy | Ice chips | No treatment | Prevention of any mucositis | No Evidence Yet | - |
CD000978.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults with head and neck cancer | Antibiotic pastille/paste | Placebo | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Acyclovir | Placebo | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Allopurinol mouthrinse | Placebo/no treatment | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Aloe vera | Placebo | Moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Benzydamine | Placebo | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Beta carotene | No treatment | Severe mucositis | No Evidence Yet | - |
| Cancer patients | Calcium phosphate | Placebo | Mucositis (all levels) | No Evidence Yet | - |
| Cancer patients | Camomile | Placebo | Mucositis (all levels) | No Evidence Yet | - |
| Cancer patients | Chlorhexidine | Placebo/no treatment | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Glutamine | Placebo | Mucositis (all levels) | No Evidence Yet | - |
| Cancer patients | GM-CSF | Placebo/no treatment | Mucositis (all levels) | No Evidence Yet | - |
| Cancer patients | Iseganan | Placebo | Mucositis (moderate/severe) | No Evidence Yet | - |
| Cancer patients | Keratinocyte GF | Placebo | Moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Povidone | Water | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Sucralfate | Placebo | Mucositis (all levels) | No Evidence Yet | - |
| Cancer patients | Systemic antibiotic (clarithromycin) | No treatment | Moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Traumeel | Placebo | Mucositis (any) | No Evidence Yet | - |
| Cancer patients | Zinc sulphate | Placebo | Moderate/severe mucositis | No Evidence Yet | - |
| Cancer patients | Zinc sulphate | Placebo | Severe mucositis | No Evidence Yet | - |
| Cancer patients receiving 5-FU | Folinic acid | No treatment | Mucositis (any) | No Evidence Yet | - |
| Head and neck cancer patients | Honey | No treatment | Severe mucositis | No Evidence Yet | - |
| Head and neck cancer patients | Hydrolytic enzymes | No treatment | Moderate/severe mucositis | No Evidence Yet | - |
| Head and neck cancer patients receiving radiotherapy | Amifostine | Placebo/no treatment | Mucositis (any) | No Evidence Yet | - |
| Head and neck cancer patients receiving radiotherapy | Amifostine | Placebo/no treatment | Moderate/severe mucositis | No Evidence Yet | - |
| Head and neck cancer patients receiving radiotherapy | Amifostine | Placebo/no treatment | Severe mucositis | No Evidence Yet | - |
| Head and neck cancer patients receiving radiotherapy | Oral care | No treatment | Mucositis (any) | No Evidence Yet | - |
| Patients receiving 5-FU | Ice chips | No treatment | Mucositis (any) | No Evidence Yet | - |
CD000978
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults receiving 5-FU chemotherapy | Ice chips | No treatment | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
| Adults receiving 5-FU chemotherapy | Ice chips | No treatment | Reduction in mucositis severity (0-1 vs 2+) | No Evidence Yet | - |
| Adults receiving chemotherapy | Allopurinol mouthrinse | Placebo/no treatment | Severe mucositis (0-2 vs 3+) | No Evidence Yet | - |
| Adults with cancer | Clarithromycin | No treatment | Reduction in mucositis severity (0-1 vs 2+) | No Evidence Yet | - |
| Adults with cancer | GM-CSF | Placebo/no treatment | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
| Adults with head and neck cancer | Antibiotic pastille/paste | Placebo | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
| Adults with head and neck cancer | Hydrolytic enzymes | No treatment | Severe mucositis (0-2 vs 3+) | No Evidence Yet | - |
| Adults with head and neck cancer | Hydrolytic enzymes | No treatment | Reduction in mucositis severity (0-1 vs 2+) | No Evidence Yet | - |
| Adults with head and neck cancer | Oral care | No treatment | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
| Adults with head and neck cancer | Povidone | Water | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
| Adults with head and neck cancer | Povidone | Water | Severe mucositis (0-2 vs 3+) | No Evidence Yet | - |
| Adults with head and neck cancer | Povidone | Water | Reduction in mucositis severity (0-1 vs 2+) | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Severe mucositis (0-2 vs 3+) | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Reduction in mucositis severity (0-1 vs 2+) | No Evidence Yet | - |
| Adults with head and neck cancer receiving radiotherapy | Amifostine | Placebo/no treatment | Prevention of mucositis (0 vs 1+) | No Evidence Yet | - |
CD000979
Current Version: CD000979.PUB3
| 2 older versions
Current Evidence Gaps 10 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| children (7 to 11 years old) with posterior crossbite | expansion plate | observation | Crossbite correction | High | None |
| children (7 to 11 years old) with posterior crossbite | quad-helix | observation | Crossbite correction | High | None |
| children (7 to 11 years old) with posterior crossbite | quad-helix | expansion plate | Molar expansion measured by intermolar distance | High | None |
| children (7 to 11 years old) with posterior crossbite | quad-helix | expansion plate | Canine expansion measured by intercanine distance | Low | Not specified |
| children (7 to 11 years old) with posterior crossbite | quad-helix | observation | Canine expansion measured by intercanine distance | Low | Not specified |
| children with posterior crossbite | bone-borne expansion | tooth?borne expansion | Molar expansion measured by inter?molar distance | Low | Not specified |
| children with posterior crossbite | bone-borne expansion | tooth?borne expansion | Crossbite correction | Low | Not specified |
| children with posterior crossbite | tooth-bone-borne expansion | Hyrax | Crossbite correction | Low | Not specified |
| children with posterior crossbite | tooth-bone-borne expansion | Hyrax | Molar expansion measured by intermolar distance | Low | Not specified |
| children (7 to 11 years old) with posterior crossbite | expansion plate | observation | Molar expansion measured by intermolar distance | Moderate | Not specified |
| children (7 to 11 years old) with posterior crossbite | expansion plate | observation | Canine expansion measured by intercanine distance | Moderate | Not specified |
| children (7 to 11 years old) with posterior crossbite | quad-helix | expansion plate | Crossbite correction | Moderate | Not specified |
| children (7 to 11 years old) with posterior crossbite | quad-helix | observation | Molar expansion measured by intermolar distance | Moderate | Not specified |
| children (7 to 11 years old) with posterior crossbite | quad-helix | expansion plate | Length of treatment measured in months | Moderate | Not specified |
| children and adolescents with posterior crossbite | Hyrax | observation | Crossbite correction | Moderate | Not specified |
| children and adolescents with posterior crossbite | Hyrax | observation | Molar expansion measured by intermolar distance | Moderate | Not specified |
| children with posterior crossbite | Hyrax | Haas | Crossbite correction | Moderate | Not specified |
| children with posterior crossbite | Hyrax | Haas | Molar expansion measured by intermolar distance | Moderate | Not specified |
| children and adolescents with posterior crossbite | Hyrax | observation | Canine expansion measured by intercanine distance | No Evidence Yet | N/A |
| children with posterior crossbite | bone-borne expansion | tooth?borne expansion | Canine expansion measured by inter?canine distance | No Evidence Yet | N/A |
| children with posterior crossbite | Hyrax | Haas | Canine expansion measured by intercanine distance | No Evidence Yet | N/A |
| children with posterior crossbite | tooth-bone-borne expansion | Hyrax | Canine expansion measured by intercanine distance | No Evidence Yet | N/A |
Previous Versions
CD000979.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Children with posterior crossbites | Fixed appliance | Removable appliance | Canine expansion (mm) (Follow up after retention period, therefore, it was variable) | Low | - |
| Children with posterior crossbites | Fixed appliance | Removable appliance | Crossbite correction (Follow up after retention period, therefore, it was variable) | Low | - |
| Children with posterior crossbites | Fixed appliance | Removable appliance | Molar expansion (mm) (Follow up after retention period, therefore, it was variable) | Moderate | - |
| Children with posterior crossbites | Fixed appliance | Removable appliance | nan | Very Low | - |
| Children with posterior crossbites | Fixed appliance ((rapid expansion) banded Hyrax (tooth borne)) | Fixed appliance ((rapid expansion) banded Hyrax (tooth/tissue borne)) | nan | Very Low | - |
| Children with posterior crossbites | Fixed appliance ((rapid expansion) banded Hyrax (tooth borne)) | Fixed appliance ((rapid expansion) banded Hyrax (tooth/tissue borne)) | Molar expansion | Very Low | - |
| Children with posterior crossbites | Fixed appliance ((rapid expansion) banded Hyrax (tooth borne)) | Fixed appliance ((rapid expansion) banded Hyrax (tooth/tissue borne)) | Molar expansion (3 months after completion of expansion phase) | Very Low | - |
CD000979
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Children with crossbite | Banded slow expansion | Bonded slow expansion | Expansion amount | No Evidence Yet | - |
| Children with crossbite | Grinding +/- URA | No treatment | Crossbite correction (post-treatment) | No Evidence Yet | - |
| Children with crossbite | Removable expansion plate | Quadhelix | Expansion amount | No Evidence Yet | - |
| Children with crossbite | Two-point expansion | Four-point Hyrax expansion | Expansion amount | No Evidence Yet | - |
| Patients with crossbite | Banded RME | Bonded RME | Expansion amount | No Evidence Yet | - |
| Patients with crossbite | TPA with buccal root torque | TPA without buccal root torque | Crossbite correction | No Evidence Yet | - |
CD001168
Current Version: CD001168.PUB3
| 2 older versions
Current Evidence Gaps 12 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| People with oral lichen planus | Topical corticosteroids | Placebo | Pain resolution | Low | Not specified |
| People with oral lichen planus | Triamcinolone | Tacrolimus | Adverse effects | Low | Not specified |
| People with oral lichen planus | Triamcinolone | Tacrolimus | Pain resolution | No Evidence Yet | N/A |
| People with oral lichen planus | Clobetasol | Tacrolimus | Adverse effects | Very Low | Not specified |
| People with oral lichen planus | Clobetasol | Tacrolimus | Pain resolution | Very Low | Not specified |
| People with oral lichen planus | Clobetasol | Ciclosporin | Clinical resolution | Very Low | Not specified |
| People with oral lichen planus | Clobetasol | Tacrolimus | Clinical resolution | Very Low | Not specified |
| People with oral lichen planus | Clobetasol | Ciclosporin | Adverse effects | Very Low | Not specified |
| People with oral lichen planus | Clobetasol | Ciclosporin | Pain resolution | Very Low | Not specified |
| People with oral lichen planus | Topical corticosteroids | Placebo | Adverse effects | Very Low | Not specified |
| People with oral lichen planus | Topical corticosteroids | Placebo | Clinical resolution | Very Low | Not specified |
| People with oral lichen planus | Triamcinolone | Tacrolimus | Clinical resolution | Very Low | Not specified |
Previous Versions
CD001168.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| OLP patients | Aloe vera | Placebo | Clinical improvement | No Evidence Yet | - |
| OLP patients | Aloe vera | Placebo | Pain reduction | No Evidence Yet | - |
| OLP patients | Antifungal+steroid | Steroid alone | Candidosis prevention | No Evidence Yet | - |
| OLP patients | BCG-PSN | Triamcinolone | Pain and clinical signs | No Evidence Yet | - |
| OLP patients | Curcuminoids+prednisone | Prednisone alone | Pain reduction | No Evidence Yet | - |
| OLP patients | Cyclosporin | Triamcinolone | Area of ulceration | No Evidence Yet | - |
| OLP patients | Cyclosporin | Placebo | Pain score | No Evidence Yet | - |
| OLP patients | Pimecrolimus | Placebo | Pain reduction | No Evidence Yet | - |
| OLP patients | Tacrolimus | Clobetasol | Pain score | No Evidence Yet | - |
| OLP patients | Western-Chinese medicine | Western medicine alone | Clinical score | No Evidence Yet | - |
CD001168
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Symptomatic oral lichen planus patients | PUVA | Placebo | Treatment response | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Systemic etretinate | Placebo | Lesion response | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical cyclosporine | Placebo | Clinical signs improvement | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical cyclosporine | Placebo | Symptomatic improvement | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical retinoids | Placebo | Combined symptom-sign response | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical steroids (Tyldesley study) | Placebo | Combined response | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical steroids (Voute study) | Placebo | Clinical signs | No Evidence Yet | - |
| Symptomatic oral lichen planus patients | Topical steroids (Voute study) | Placebo | Symptoms | No Evidence Yet | - |
CD001476
Current Version: CD001476.PUB2
| 1 older version
Current Evidence Gaps 5 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Control toothpaste without potassium nitrate | Subjective assessment | No Evidence Yet | N/A |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Control toothpaste without potassium nitrate | Tactile sensitivity (method b) | No Evidence Yet | N/A |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Control toothpaste without potassium nitrate | Tactile sensitivity (method a) | No Evidence Yet | N/A |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Control toothpaste without potassium nitrate | Air blast sensitivity | No Evidence Yet | N/A |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Control toothpaste without potassium nitrate | Thermal sensitivity | No Evidence Yet | N/A |
Previous Versions
CD001476
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Placebo toothpaste | Air blast sensitivity | No Evidence Yet | - |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Placebo toothpaste | Tactile sensitivity (method b) | No Evidence Yet | - |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Placebo toothpaste | Tactile sensitivity (method a) | No Evidence Yet | - |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Placebo toothpaste | Subjective assessment | No Evidence Yet | - |
| Patients with dentine hypersensitivity | 5% potassium nitrate toothpaste | Placebo toothpaste | Thermal sensitivity | No Evidence Yet | - |
CD001724
Current Version: CD001724.PUB2
| 1 older version
Current Evidence Gaps 11 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients with periodontal defects | GTR alone | Open flap debridement | Attachment gain | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR alone | Open flap debridement | Probing depth reduction | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR alone | Open flap debridement | Sites gaining <2mm attachment | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR alone | Open flap debridement | Gingival recession | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR alone | Open flap debridement | Bone gain (surgical re-entry) | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Gingival recession | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Bone gain (surgical re-entry) | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Probing depth reduction | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Attachment gain | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR (parallel group studies) | Open flap debridement | Attachment gain | No Evidence Yet | N/A |
| Patients with periodontal defects | GTR (split-mouth studies) | Open flap debridement | Attachment gain | No Evidence Yet | N/A |
Previous Versions
CD001724
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with periodontal defects | GTR alone | Open flap debridement | Change in attachment level | No Evidence Yet | - |
| Patients with periodontal defects | GTR alone | Open flap debridement | Change in probing depth | No Evidence Yet | - |
| Patients with periodontal defects | GTR alone | Open flap debridement | Sites gaining <2mm attachment | No Evidence Yet | - |
| Patients with periodontal defects | GTR alone | Open flap debridement | Gingival recession | No Evidence Yet | - |
| Patients with periodontal defects | GTR alone | Open flap debridement | Hard tissue probing gain | No Evidence Yet | - |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Hard tissue probing gain | No Evidence Yet | - |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Gingival recession | No Evidence Yet | - |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Change in probing depth | No Evidence Yet | - |
| Patients with periodontal defects | GTR + bone substitutes | Open flap debridement | Change in attachment level | No Evidence Yet | - |
CD001829
Current Version: CD001829.PUB4
| 3 older versions
Current Evidence Gaps 23 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| People with oral leukoplakia | Bowman-Birk inhibitor | Placebo | Clinical resolution (not completely resolved) at 6 months | Low | Not specified |
| People with oral leukoplakia | Systemic beta carotene | Placebo | Histological changes (not improved) at 5 months (treatment lasted 3 months) | Low | Not specified |
| People with oral leukoplakia | Vitamin A or retinoids | Placebo | Histological changes (not improved) at 3 months | Moderate | Not specified |
| People with oral leukoplakia | Bowman-Birk inhibitor | Placebo | Histological changes (not improved) at 6 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Bowman-Birk inhibitor | Placebo | Safety of the intervention up to 6 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Bowman-Birk inhibitor | Placebo | Cancer development | No Evidence Yet | N/A |
| People with oral leukoplakia | herbal extracts a tea components; a Chinese herbal mixture; curcumin chewing gum; freeze dried black raspberry gel | Placebo | Clinical resolution (not completely resolved) at 3 to 6 months | No Evidence Yet | N/A |
| People with oral leukoplakia | herbal extracts a tea components; a Chinese herbal mixture; curcumin chewing gum; freeze dried black raspberry gel | Placebo | Histological changes (not improved) at 3 months | No Evidence Yet | N/A |
| People with oral leukoplakia | herbal extracts a tea components; a Chinese herbal mixture; curcumin chewing gum; freeze dried black raspberry gel | Placebo | Safety of the intervention over 3 months | No Evidence Yet | N/A |
| People with oral leukoplakia | herbal extracts a tea components; a Chinese herbal mixture; curcumin chewing gum; freeze dried black raspberry gel | Placebo | Cancer development | No Evidence Yet | N/A |
| People with oral leukoplakia | NSAIDs | Placebo | Clinical resolution (not completely resolved) at 3 months | No Evidence Yet | N/A |
| People with oral leukoplakia | NSAIDs | Placebo | Cancer development | No Evidence Yet | N/A |
| People with oral leukoplakia | NSAIDs | Placebo | Histological changes (not improved) | No Evidence Yet | N/A |
| People with oral leukoplakia | NSAIDs | Placebo | Safety of the intervention over 3 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Systemic beta carotene | Placebo | Safety of the intervention at 5 to 12 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Systemic beta carotene | Placebo | Clinical resolution (not completely resolved) at 5 to 12 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Topical bleomycin | Placebo | Safety of the intervention over 3 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Vitamin A or retinoids | Placebo | Safety of the intervention at 4 to 12 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Vitamin A or retinoids | Placebo | Clinical resolution (not completely resolved) at 4 to 12 months | No Evidence Yet | N/A |
| People with oral leukoplakia | Systemic beta carotene | Placebo | Cancer development at 24 months from start of treatment (treatment lasted 12 months) | Very Low | Not specified |
| People with oral leukoplakia | Topical bleomycin | Placebo | Cancer development up to 7 years | Very Low | Not specified |
| People with oral leukoplakia | Topical bleomycin | Placebo | Clinical resolution (not completely resolved) at 3 months | Very Low | Not specified |
| People with oral leukoplakia | Topical bleomycin | Placebo | Histological changes (not improved) at 3 months | Very Low | Not specified |
| People with oral leukoplakia | Vitamin A or retinoids | Placebo | Cancer development at 24 months from start of treatment (treatment lasted 12 months) | Very Low | Not specified |
Previous Versions
CD001829.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with oral leukoplakia | Beta carotene/lycopene | Placebo | Clinical resolution | No Evidence Yet | - |
| Patients with oral leukoplakia | Bleomycin/vitamin A/beta carotene | Placebo | Malignant transformation | No Evidence Yet | - |
| Patients with oral leukoplakia | Lycopene | Placebo | Histological improvement | No Evidence Yet | - |
| Patients with oral leukoplakia | Retinoic acid | Placebo | Histological improvement | No Evidence Yet | - |
| Patients with oral leukoplakia | Vitamin A/retinoids | Placebo | Clinical resolution | No Evidence Yet | - |
CD001829.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with oral leukoplakia | Beta carotene | Placebo | Clinical resolution | No Evidence Yet | - |
| Patients with oral leukoplakia | Beta carotene | Placebo | Malignant transformation | No Evidence Yet | - |
| Patients with oral leukoplakia | Bleomycin | Placebo | Malignant transformation | No Evidence Yet | - |
| Patients with oral leukoplakia | Systemic 13-cis-retinoic acid | Placebo | Histological worsening | No Evidence Yet | - |
| Patients with oral leukoplakia | Vitamin A | Placebo | Malignant transformation | No Evidence Yet | - |
| Patients with oral leukoplakia | Vitamin A/retinoids | Placebo | Clinical resolution | No Evidence Yet | - |
CD001829
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with oral leukoplakia | 13-cis-retinoic acid | Placebo | Histological worsening | No Evidence Yet | - |
| Patients with oral leukoplakia | Beta carotene | Placebo | Clinical resolution | No Evidence Yet | - |
| Patients with oral leukoplakia | Vitamin A/retinoids | Placebo | Clinical resolution | No Evidence Yet | - |
CD001830
Current Version: CD001830.PUB5
| 1 older version
Current Evidence Gaps 4 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children and adolescents | Resin-based sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Dentine caries in permanent molars (16% incidence in control group) | Moderate | Not specified |
| Children and adolescents | Resin-based sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Dentine caries in permanent molars (70% incidence in control group) | Moderate | Not specified |
| Children and adolescents | Resin-based sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Dentine caries in permanent molars (40% incidence in control group) | Moderate | Not specified |
| Children and adolescents | Low viscosity glass ionomer sealant (including Fuji III, VII, GC Fuji Triage White, Ketac Silver, Ketac fil or Baseline); high viscosity glass ionomer (including Fuji IX or Ketac Molar Easymix), and resin modified glass ionomer (including Fuji II LC, Vitrebond or Vitremer) | Resin sealant | Adverse effects | No Evidence Yet | N/A |
| Children and adolescents | Resin-based sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Adverse effects | No Evidence Yet | N/A |
| Children and adolescents | Low-viscosity glass ionomer sealant (Fuji III and VII), and resin-modified glass ionomer (Vitremer) | No sealant application | Dentine caries in permanent molars | Very Low | Not specified |
| Children and adolescents | Low viscosity glass ionomer sealant (including Fuji III, VII, GC Fuji Triage White, Ketac Silver, Ketac fil or Baseline); high viscosity glass ionomer (including Fuji IX or Ketac Molar Easymix), and resin modified glass ionomer (including Fuji II LC, Vitrebond or Vitremer) | Resin sealant | Dentine caries in permanent molars | Very Low | Not specified |
Previous Versions
CD001830.PUB4
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Children and adolescents | Resin-based sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Dentine caries in permanent molars (2 years follow-up) | Moderate | - |
| Children and adolescents | Glass ionomer sealant applications on occlusal tooth surfaces of permanent molars | No sealant application | Caries as DFS increment in permanent molars (2 years follow-up) | Very Low | - |
| Children and adolescents | Glass ionomer sealant (including Fuji III, VII, IX, Ketac Silver, Ketacâ fil, Ketac Molar Easymix or Baseline) | Resin sealant | Dentine caries in permanent molars (Follow up: 1, 2, 3, 4, 5 and 7 years) | Very Low | - |
| Children and adolescents | Polyacid-modified resin composite | Resin sealant | Dentine caries in permanent molars | Very Low | - |
| Children and adolescents | Resin-modified glass ionomer sealant (Fuji II LC, Vitrebond or Vitremer) | Resin sealant (Helioseal, Tetric Flow, Fluoroshield or Concise White) | Dentine caries in permanent molars (Follow up: 1, 2 and 3 years) | Very Low | - |
CD001972
Current Version: CD001972.PUB4
| 3 older versions
Current Evidence Gaps 5 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Cancer patients | Absorbed drugs | Non-absorbed drugs | Mycological eradication of oral candidiasis | No Evidence Yet | N/A |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Mycological eradication of oral candidiasis | No Evidence Yet | N/A |
| Cancer patients | Fluconazole | Itraconazole | Mycological eradication of oral candidiasis | No Evidence Yet | N/A |
| Cancer patients | Fluconazole/Ketoconazole | Nystatin/Amphotericin B | Clinical eradication of oral candidiasis | No Evidence Yet | N/A |
| Cancer patients | Ketoconazole | Placebo | Clinical eradication of oral candidiasis | No Evidence Yet | N/A |
Previous Versions
CD001972.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Mycological eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Fluconazole | Nystatin | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Ketoconazole | Placebo | Clinical eradication of oral candidiasis | No Evidence Yet | - |
CD001972.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients | Absorbed antifungals | Non-absorbed antifungals | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole | Placebo | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Mycological eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Ketoconazole | Placebo | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients (overall) | Various antifungals | Various comparators | All outcomes combined | No Evidence Yet | - |
CD001972
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients | Absorbed drugs | Non-absorbed drugs | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Mycological eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Clotrimazole 50mg | Clotrimazole 10mg | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients | Ketoconazole | Placebo | Clinical eradication of oral candidiasis | No Evidence Yet | - |
| Cancer patients (overall) | Various antifungals | Various comparators | All outcomes combined | No Evidence Yet | - |
CD001973
Current Version: CD001973.PUB4
| 3 older versions
Current Evidence Gaps 14 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Cancer patients with mucositis | Allopurinol | Placebo | Time to heal mucositis (days) | No Evidence Yet | N/A |
| Cancer patients with mucositis | Benzydamine HCl | Placebo | Improvement in mucositis | No Evidence Yet | N/A |
| Cancer patients with mucositis | Cognitive behaviour therapy | Control | Average pain score | No Evidence Yet | N/A |
| Cancer patients with mucositis | GM-CSF | Povidone iodine | Time to heal mucositis (days) | No Evidence Yet | N/A |
| Cancer patients with mucositis | GM-CSF | Antimycotic mouthwash | Time to heal mucositis (days) | No Evidence Yet | N/A |
| Cancer patients with mucositis | Human placental extract | Disprin | Improvement in mucositis | No Evidence Yet | N/A |
| Cancer patients with mucositis | Laser | Sham treatment | Mild to moderate mucositis | No Evidence Yet | N/A |
| Cancer patients with mucositis | PCA morphine | Continuous infusion morphine | Duration of pain control (days) | No Evidence Yet | N/A |
| Cancer patients with mucositis | PCA morphine | Continuous infusion morphine | Daily mean opiate intake (mg/hr) | No Evidence Yet | N/A |
| Cancer patients with mucositis | PCA morphine | Continuous infusion morphine | Mean pain score | No Evidence Yet | N/A |
| Cancer patients with mucositis | Polyvariant immunoglobulin | Placebo | Improvement in mucositis | No Evidence Yet | N/A |
| Cancer patients with mucositis | Sucralfate | Placebo | Eradication of mucositis | No Evidence Yet | N/A |
| Cancer patients with mucositis | Therapist visits | Control | Average pain score | No Evidence Yet | N/A |
| Cancer patients with mucositis | Vitamin E topical | Vitamin E swallowed | Improvement in mucositis | No Evidence Yet | N/A |
Previous Versions
CD001973.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients with mucositis | Allopurinol | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol | Placebo | Mucositis eradication | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol | Placebo | Time to heal mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | GM-CSF | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | GM-CSF | Povidone iodine | Time to heal mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Human placental extract | Control | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Polyvariant intramuscular immunoglobulin | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis pain | Alfentanil PCA | Morphine PCA | Daily morphine intake | No Evidence Yet | - |
| Cancer patients with mucositis pain | Morphine | Nortriptyline | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis pain | Morphine PCA | Morphine PKPCA | Daily morphine intake | No Evidence Yet | - |
| Cancer patients with mucositis pain | Morphine PKPCA | Morphine PCA | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis pain | PCA | Continuous infusion | Duration of pain control therapy | No Evidence Yet | - |
| Cancer patients with mucositis pain | PCA morphine | Continuous infusion morphine | Daily morphine intake | No Evidence Yet | - |
CD001973.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients with mucositis | Alfentanil PCA | Morphine PCA | Daily morphine intake | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol | Placebo | Mucositis eradication | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol | Placebo | Time to heal mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | GM-CSF | Povidone iodine | Time to heal mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Human placental extract | Control | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Morphine | Nortriptyline | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis | Morphine PCA | Morphine PKPCA | Daily morphine intake | No Evidence Yet | - |
| Cancer patients with mucositis | Morphine PKPCA | Morphine PCA | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis | PCA | Continuous infusion | Duration of pain control therapy | No Evidence Yet | - |
| Cancer patients with mucositis | PCA morphine | Continuous infusion morphine | Daily morphine intake | No Evidence Yet | - |
| Cancer patients with mucositis | Polyvariant intramuscular immunoglobulin | Placebo | Improvement in mucositis | No Evidence Yet | - |
CD001973
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Cancer patients with mucositis | Allopurinol | Placebo | Mucositis eradication | No Evidence Yet | - |
| Cancer patients with mucositis | Allopurinol mouthwash | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Benzydamine mouthwash | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Chlorhexidine/magic mouthwash | Salt and soda | Mucositis eradication | No Evidence Yet | - |
| Cancer patients with mucositis | Morphine PKPCA | Morphine PCA | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis | PCA morphine | CI morphine | Daily morphine utilization (mg/hr) | No Evidence Yet | - |
| Cancer patients with mucositis | Sucralfate | Placebo | Mucositis eradication | No Evidence Yet | - |
| Cancer patients with mucositis | Tetrachlorodecaoxide | Placebo | Improvement in mucositis | No Evidence Yet | - |
| Cancer patients with mucositis | Therapist/relaxation/imagery | Control | Pain scores | No Evidence Yet | - |
| Cancer patients with mucositis | Vitamin E | Placebo | Mucositis eradication | No Evidence Yet | - |
CD002278
Current Version: CD002278
Current Evidence Gaps 7 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children aged 5-16 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | D(M)FT standardized difference | No Evidence Yet | N/A |
| Children aged 5-16 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | D(M)FS standardized difference | No Evidence Yet | N/A |
| Children aged 5-16 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | D(M)FT prevented fraction | No Evidence Yet | N/A |
| Children aged 5-16 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | D(M)FS prevented fraction | No Evidence Yet | N/A |
| Children aged 5-16 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | Proportion developing new caries | No Evidence Yet | N/A |
| Children aged 5-16 years | Stannous fluoride toothpaste | Placebo toothpaste | Proportion with tooth staining | No Evidence Yet | N/A |
| Children aged 6-9 years | Fluoride toothpaste | Placebo/non-fluoride toothpaste | df-rate in deciduous teeth | No Evidence Yet | N/A |
CD002279
Current Version: CD002279.PUB2
| 1 older version
Current Evidence Gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children and adolescents | Fluoride varnish | No treatment/placebo | Permanent tooth surfaces D(M)FS increment PF - nearest to 3 years | Moderate | Not specified |
| Children and adolescents | Fluoride varnish | No treatment/placebo | Deciduous tooth surfaces d((e)/m)fs increment PF - nearest to 3 years | Moderate | Not specified |
Previous Versions
CD002279
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | Deciduous teeth caries (d(e/m)fs standardized difference) | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | Treatment discontinuation (dropouts) | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | Proportion developing new caries | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | Deciduous teeth caries (d(e/m)fs prevented fraction) | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | D(M)FT standardized difference | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | D(M)FS standardized difference | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | D(M)FT prevented fraction | No Evidence Yet | - |
| Children aged 3-15 years | Fluoride varnish | Placebo or no treatment | D(M)FS prevented fraction | No Evidence Yet | - |
CD002280
Current Version: CD002280.PUB2
| 1 older version
Current Evidence Gaps 2 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children and adolescents | Fluoride gel | Placebo or no treatment | Changes in caries on the surfaces of primary teeth | Low | Not specified |
| Children and adolescents | Fluoride gel | Placebo or no treatment | Changes in caries on the surfaces of permanent teeth | Moderate | Not specified |
| Children and adolescents | Fluoride gel | Placebo or no treatment | Signs of acute toxicity - nausea, vomiting | Very Low | Not specified |
Previous Versions
CD002280
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Children aged 2-15 years | Fluoride gel | Placebo/No treatment | Proportion not remaining caries-free | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | Placebo/No treatment | Proportion developing new caries | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | No treatment | D(M)FT prevented fraction | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | Placebo | D(M)FT prevented fraction | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | No treatment | D(M)FS prevented fraction | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | Placebo | D(M)FS prevented fraction | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | Placebo/No treatment | Adverse events (nausea/vomiting) | No Evidence Yet | - |
| Children aged 2-15 years | Fluoride gel | No treatment | Treatment discontinuation | No Evidence Yet | - |
CD002281
Current Version: CD002281.PUB3
| 2 older versions
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Individuals of any age with no reported disability that might affect toothbrushing | Powered toothbrushes with any mode of action | Manual toothbrushes | Plaque scores at 1 to 3 months | Moderate | Not specified |
| Individuals of any age with no reported disability that might affect toothbrushing | Powered toothbrushes with any mode of action | Manual toothbrushes | Gingival scores at 1 to 3 months | Moderate | Not specified |
| Individuals of any age with no reported disability that might affect toothbrushing | Powered toothbrushes with any mode of action | Manual toothbrushes | Adverse events | No Evidence Yet | N/A |
Previous Versions
CD002281.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults with teeth | Circular powered toothbrush | Manual toothbrush | Plaque and gingivitis | No Evidence Yet | - |
| Adults with teeth | Counter oscillation powered toothbrush | Manual toothbrush | Plaque (>3 months) | No Evidence Yet | - |
| Adults with teeth | Ionic powered toothbrush | Manual toothbrush | Plaque (>3 months) | No Evidence Yet | - |
| Adults with teeth | Ionic powered toothbrush | Manual toothbrush | Gingivitis (>3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Gingivitis (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Gingivitis (>3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Plaque (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Side to side powered toothbrush | Manual toothbrush | Plaque (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Side to side powered toothbrush | Manual toothbrush | Gingivitis (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Ultrasonic powered toothbrush | Manual toothbrush | Gingivitis (<3 months) | No Evidence Yet | - |
| Adults with teeth | Unknown powered toothbrush | Manual toothbrush | Gingivitis (<3 months) | No Evidence Yet | - |
CD002281
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults with teeth | Circular powered toothbrush | Manual toothbrush | Plaque and gingivitis | No Evidence Yet | - |
| Adults with teeth | Counter oscillation powered toothbrush | Manual toothbrush | Plaque (>3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Gingivitis (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Plaque (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Plaque (>3 months) | No Evidence Yet | - |
| Adults with teeth | Rotation oscillation powered toothbrush | Manual toothbrush | Gingivitis (>3 months) | No Evidence Yet | - |
| Adults with teeth | Side to side powered toothbrush | Manual toothbrush | Gingivitis (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Side to side powered toothbrush | Manual toothbrush | Plaque (1-3 months) | No Evidence Yet | - |
| Adults with teeth | Ultrasonic powered toothbrush | Manual toothbrush | Plaque (1-3 months) | No Evidence Yet | - |
CD002282
Current Version: CD002282.PUB2
| 1 older version
Current Evidence Gaps 4 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Orthodontic patients | Chemical cured composite | Glass ionomer cement | Bracket failure rate | No Evidence Yet | N/A |
| Orthodontic patients | Chemical cured composite | Light cured composite | Bracket failure rate | No Evidence Yet | N/A |
| Orthodontic patients | Chemical cured composite | Compomer (Dyract Ortho) | Bracket failure rate | No Evidence Yet | N/A |
| Orthodontic patients | Chemical cured composite | Compomer (Dyract Ortho) | Decalcification | No Evidence Yet | N/A |
Previous Versions
CD002282
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Orthodontic patients | Chemical cured composite | Glass ionomer cement | Bracket failure rate | No Evidence Yet | - |
| Orthodontic patients | Chemical cured composite (Right-On) | Compomer (Dyract Ortho) | Bracket failure rate | No Evidence Yet | - |
| Orthodontic patients | Chemical cured composite (Right-On) | Compomer (Dyract Ortho) | Decalcification | No Evidence Yet | - |
| Orthodontic patients | Light cured composite | Chemical cured composite | Bracket failure rate | No Evidence Yet | - |
CD002283
Current Version: CD002283.PUB5
| 3 older versions
Current Evidence Gaps 28 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| People who had received fixed appliance treatment | CAD/CAM nitinol fixed retainer | Conventional/analogue multistrand fixed retainer | Adverse effects on oral health (Gingival Index) | Low | Not specified |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Survival (Failure of retainer) | Low | Not specified |
| People who had received fixed appliance treatment | CAD/CAM nitinol fixed retainer | Conventional/analogue multistrand fixed retainer | Patient satisfaction (Discomfort/pain) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | CAD/CAM nitinol fixed retainer | Conventional/analogue multistrand fixed retainer | Adverse effects on oral health (Bleeding on probing) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Survival (Mean survival time) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Adverse effects on oral health (Gingival Index) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Adverse effects on oral health (Bleeding on probing) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Full-time wear of any type of removable retainer | Part-time wear of any type of removable retainer | Adverse effects on oral health | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Full-time wear of any type of removable retainer | Part-time wear of any type of removable retainer | Survival | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Full-time wear of any type of removable retainer | Part-time wear of any type of removable retainer | Patient satisfaction | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Hawley removable retainer (any coincident wearing protocol between treatment arms) | Clear plastic removable retainer (any coincident wearing protocol between treatment arms) | Adverse effects on oral health | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | Hawley removable retainer (any coincident wearing protocol between treatment arms) | Clear plastic removable retainer (any coincident wearing protocol between treatment arms) | Patient satisfaction (Comfort) | No Evidence Yet | N/A |
| People who had received fixed appliance treatment | CAD/CAM nitinol fixed retainer | Conventional/analogue multistrand fixed retainer | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | CAD/CAM nitinol fixed retainer | Conventional/analogue multistrand fixed retainer | Survival (Failure of retainer) | Very Low | Not specified |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Patient satisfaction (Aesthetic) | Very Low | Not specified |
| People who had received fixed appliance treatment | Fibre-reinforced composite retainer | Multistrand/spiral wire fixed retainer | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time clear plastic removable retainer | Any type of fixed retainer | Survival (Failure of retainer) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time clear plastic removable retainer | Any type of fixed retainer | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time clear plastic removable retainer | Any type of fixed retainer | Patient satisfaction (Discomfort/pain) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time clear plastic removable retainer | Any type of fixed retainer | Adverse effects on oral health (Caries) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time clear plastic removable retainer | Any type of fixed retainer | Adverse effects on oral health (Gingival bleeding) | Very Low | Not specified |
| People who had received fixed appliance treatment | Full-time wear of any type of removable retainer | Part-time wear of any type of removable retainer | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | Hawley removable retainer (any coincident wearing protocol between treatment arms) | Clear plastic removable retainer (any coincident wearing protocol between treatment arms) | Survival (Failure of retainer) | Very Low | Not specified |
| People who had received fixed appliance treatment | Hawley removable retainer (any coincident wearing protocol between treatment arms) | Clear plastic removable retainer (any coincident wearing protocol between treatment arms) | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | Part-time clear plastic removable retainers | Any type of fixed retainer | Patient satisfaction (Discomfort/pain) | Very Low | Not specified |
| People who had received fixed appliance treatment | Part-time clear plastic removable retainers | Any type of fixed retainer | Stability (Little's Irregularity Index) | Very Low | Not specified |
| People who had received fixed appliance treatment | Part-time clear plastic removable retainers | Any type of fixed retainer | Survival (Failure of retainer) | Very Low | Not specified |
| People who had received fixed appliance treatment | Part-time clear plastic removable retainers | Any type of fixed retainer | Adverse effects on oral health (Gingival Index) | Very Low | Not specified |
Previous Versions
CD002283.PUB4
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| People who had received fixed appliance treatment | Removable retainers | Fixed retainers | Patient satisfaction | Low | - |
| People who had received fixed appliance treatment | Removable retainers | Fixed retainers | Adverse effects on health (gingival bleeding) | Low | - |
| People who had received fixed appliance treatment | Removable retainers | Fixed retainers | Stability - Little's Irregularity Index in lower arch | Low | - |
| People who have received fixed appliance treatment | One type of fixed retainer | Another type of fixed retainer | Failure of retainers (lower arch) | Low | - |
| People who have received fixed appliance treatment | One type of removable retainer or wear time | Another type of removable retainer or wear time | Patient satisfaction (Embarrassed to wear retainer) | Low | - |
| People who have received fixed appliance treatment | One type of removable retainer or wear time | Another type of removable retainer or wear time | Failure of retainers | Low | - |
| People who have received fixed appliance treatment | One type of fixed retainer | Another type of fixed retainer | Adverse effects on health | No Evidence Yet | - |
| People who have received fixed appliance treatment | One type of fixed retainer | Another type of fixed retainer | Stability - Little's Irregularity Index | No Evidence Yet | - |
| People who have received fixed appliance treatment | One type of fixed retainer | Another type of fixed retainer | Patient satisfaction | No Evidence Yet | - |
| People who have received fixed appliance treatment | One type of removable retainer or wear time | Another type of removable retainer or wear time | Adverse effects on health | No Evidence Yet | - |
| People who had received fixed appliance treatment | Removable retainers | Fixed retainers | Failure of retainers (lower) | Very Low | - |
CD002283.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Orthodontic patients | CSF + full-time removable retainer | Full-time removable retainer only | Maxillary anterior stability | No Evidence Yet | - |
| Orthodontic patients | CSF + full-time removable retainer | Full-time removable retainer only | Mandibular anterior stability | No Evidence Yet | - |
| Orthodontic patients | CSF + night-only retainer | Night-only retainer | Change in keratinized gingiva | No Evidence Yet | - |
| Orthodontic patients | CSF + night-only retainer | Night-only retainer | Change in epithelial attachment | No Evidence Yet | - |
| Orthodontic patients | Hawley retainer | Clear overlay retainer | Number of occlusal contacts | No Evidence Yet | - |
| Orthodontic patients | Resin bonded retainer | Multistrand wire retainer | Retainer failure rate | No Evidence Yet | - |
CD002283.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Orthodontic patients | CSF + full-time removable retainer | Full-time removable retainer only | Mandibular anterior segment stability | No Evidence Yet | - |
| Orthodontic patients | CSF + full-time removable retainer | Full-time removable retainer only | Maxillary anterior segment stability | No Evidence Yet | - |
| Orthodontic patients | CSF + night-only retainer | Night-only retainer | Change in keratinized gingiva | No Evidence Yet | - |
| Orthodontic patients | CSF + night-only retainer | Night-only retainer | Change in epithelial attachment | No Evidence Yet | - |
| Orthodontic patients | Hawley retainer | Clear overlay retainer | Number of occlusal contacts | No Evidence Yet | - |
Showing 1 to 20 of 214 review series
Summary Statistics
214
Review Series
3688
PICO Questions
Evidence Certainty
High
(%)
Moderate
(%)
Low
(%)
Very Low
(%)
No Evidence Yet
(%)
GRADE Downgrading Reasons
Risk of Bias
985
(85.8%)
Imprecision
895
(78.0%)
Inconsistency
253
(22.0%)
Indirectness
188
(16.4%)
Publication Bias
48
(4.2%)